IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Integris Medtech
IPO is a MainBoard Upcoming IPO coming on
BSE,NSE with an
IPO
size of
[●]
.
This IPO falls under the
Pharmaceutical sector, which has seen
25 IPOs
to date. Key sector metrics such as average PE ratio, IPO size, EBITDA margin,
and
PAT margin are compared below with the figures from the
Integris Medtech
IPO.
Integris Medtech IPO Peer Comparison with key metrics mentioned in the DRHP.
| Company Name | Type | FV | CMP | PE | Revenue | Basic EPS | Diluted EPS | RONW % | NAV |
|---|---|---|---|---|---|---|---|---|---|
| Integris Medtech Limited | Consolidated | 1 | 1902.47 | 5.82 | 5.73 | 1.84 | 316.09 | ||
| Poly Medicure Limited | Consolidated | 5 | 1911.00 | 56.02 | 1669.83 | 34.13 | 34.11 | 12.26 | 278.46 |
| Laxmi Dental Limited | Consolidated | 2 | 326.40 | 53.95 | 239.11 | 6.07 | 6.05 | 16.09 | 37.71 |
1. All the financial information of the Company mentioned above has been derived from the Restated Consolidated Financial Information at and for the financial year ended March 31, 2025.
2. Closing Price per share is closing price in NSE as on October 8, 2025.
3. P/E has been computed as market price per share as on October 8, 2025 divided by net diluted earnings per share for the year ended March 31, 2025.
4. Basic EPS (₹) = Basic earnings per share are calculated by dividing the net restated profit or loss for the year attributable to equity shareholders by the weighted average number of Equity Shares outstanding during the year.
5. Diluted EPS (₹) = Diluted earnings per share are calculated by dividing the net restated profit or loss for the year attributable to equity shareholders by the weighted average number of Equity Shares outstanding during the year as adjusted for the effects of all dilutive potential Equity Shares outstanding during the year.
6. Weighted average number of Equity Shares is the number of Equity Shares outstanding at the beginning of the year adjusted by the number of Equity Shares issued during the year multiplied by the time weighting factor. The time weighting factor is the number of days for which the specific shares are outstanding as a proportion of total number of days during the year.
7. Return on Net Worth (%) = Net Profit after tax attributable to owners of our Company divided by net worth at the end of the respective year/ period as per the Restated Consolidated Financial Information.
8. Net Worth is calculated as equity share capital plus other equity less capital reserves less common control adjustments deficit accounts and foreign currency translation reserve.
9. Net Asset Value per Equity Share = Net worth in accordance with the Restated Consolidated Financial Information/ Weighted Average Number of equity shares outstanding for the purpose of calculation of basic EPS as of the end of the year.
10. For the Company, all the numbers have been taken from Restated Consolidated Financial Information. For others, all the numbers have been sourced from the F&S Report
You can do performance analysis for Integris Medtech IPO with Listed IPOs in the Pharmaceutical sector and review their IPO performance based on Merchant banker, Listing price, IPO Valuation and other metrics.
This IPO report captures the post-listing performance of IPOs in the Pharmaceutical sector, featuring key metrics like offer price, listing gain, and CMP to help investors assess return potential and sector sentiment.
| NAME | OFFER PRICE | LISTING PRICE | LISTING GAIN | CMP | CMP % |
|---|---|---|---|---|---|
|
Amanta Healthcare
IPO
Financial Report >> |
₹ 126.00 | ₹ 135.00 | 7.14% | ₹ 134 | 6% |
|
Anlon Healthcare
IPO
Financial Report >> |
₹ 91.00 | ₹ 92.00 | 1.10% | ₹ 129 | 42% |
|
Anthem Biosciences
IPO
Financial Report >> |
₹ 570.00 | ₹ 723.05 | 26.85% | ₹ 801 | 40% |
|
Senores Pharmaceuticals
IPO
Financial Report >> |
₹ 391.00 | ₹ 609.00 | 55.75% | ₹ 732 | 87% |
|
Akums Drugs
IPO
Financial Report >> |
₹ 679.00 | ₹ 796.35 | 17.28% | ₹ 446 | -34% |
|
Emcure Pharmaceuticals
IPO
Financial Report >> |
₹ 1,008.00 | ₹ 1,358.85 | 34.81% | ₹ 1,423 | 41% |
|
Indegene Limited
IPO
Financial Report >> |
₹ 452.00 | ₹ 570.65 | 26.25% | ₹ 557 | 23% |
|
Innova Captab
IPO
Financial Report >> |
₹ 448.00 | ₹ 545.15 | 21.69% | ₹ 837 | 87% |
|
Blue Jet
IPO
Financial Report >> |
₹ 346.00 | ₹ 395.85 | 14.41% | ₹ 678 | 96% |
|
Valiant Laboratories
IPO
Financial Report >> |
₹ 140.00 | ₹ 169.05 | 20.75% | ₹ 87 | -38% |
|
Concord Biotech
IPO
Financial Report >> |
₹ 741.00 | ₹ 941.85 | 27.11% | ₹ 1,603 | 116% |
|
Mankind Pharma
IPO
Financial Report >> |
₹ 1,080.00 | ₹ 1,424.05 | 31.86% | ₹ 2,460 | 128% |
|
Supriya Lifescience
IPO
Financial Report >> |
₹ 274.00 | ₹ 390.35 | 42.46% | ₹ 722 | 164% |
|
Medplus Health
IPO
Financial Report >> |
₹ 796.00 | ₹ 1,120.85 | 40.81% | ₹ 784 | -1% |
|
Windlas Biotech
IPO
Financial Report >> |
₹ 460.00 | ₹ 406.70 | 406.70% | ₹ 915 | 99% |
|
Glenmark Life
IPO
Financial Report >> |
₹ 720.00 | ₹ 748.20 | 748.20% | ₹ 934 | 30% |
|
Gland Pharma
IPO
Financial Report >> |
₹ 1,500.00 | ₹ 1,820.45 | 1820.45% | ₹ 1,923 | 28% |
|
Eris Lifesciences
IPO
Financial Report >> |
₹ 603.00 | ₹ 601.05 | 601.05% | ₹ 1,596 | 165% |
|
Laurus Labs
IPO
Financial Report >> |
₹ 428.00 | ₹ 480.50 | 480.50% | ₹ 877 | 924% |
|
Alkem Laboratories
IPO
Financial Report >> |
₹ 1,050.00 | ₹ 1,381.45 | 1381.45% | ₹ 5,455 | 419% |
|
Syngene International
IPO
Financial Report >> |
₹ 250.00 | ₹ 310.40 | 310.40% | ₹ 651 | 161% |
|
Brooks Laboratories
IPO
Financial Report >> |
₹ 100.00 | ₹ 60.20 | -39.80% | ₹ 125 | 25% |
|
Parabolic Drugs
IPO
Financial Report >> |
₹ 75.00 | ₹ 64.80 | 64.80% | [●] | 0.00% |
|
Bafna Pharmaceuticals
IPO
Financial Report >> |
₹ 40.00 | ₹ 38.50 | 38.50% | [●] | 0.00% |
|
SMS Pharmaceuticals
IPO
Financial Report >> |
₹ 380.00 | ₹ 357.85 | 357.85% | ₹ 275 | 623% |
Integris Medtech IPO Draft red herring prospectus (DRHP) and Red Herring prospectus (RHP) are available below.
The peers of
Integris Medtech ,
include other listed companies operating in the
(Pharmaceutical) segment.
These peer companies typically
offer similar services Some of the notable peers as per the DRHP of this
company
are
Integris Medtech Limited ,
Poly Medicure Limited
Laxmi Dental Limited ,
See the complete list of
current IPO
Peer Comparison is the method of evaluating an entity by comparing its performance, size of business form other entities operating in same industry or sector. It involves financial analysis by comparing key financial metrics like Profitability, Net worth, Market Capitalization and Leverage IPO Performance tracker
Peer comparison helps to identify companies in the same sector with a similar business. It helps to compare the financial performance and valuation against its listed peers. An investor or an analyst can decide whether the IPO price is justified when compared to its peers. An investor can make informed decision whether to apply to IPO or not on basis of peer comparison. Know the process of DRHP and Peer companies Information required to be disclosed in DRHP.
As of now 25 IPOs are listed in this sector indicating strong growth in this sector. Choosing the best IPO depends on factors like, financial performance, valuation, market trends and future growth plans. IPO Review and performance.
A good PE Ratio for Pharmaceutical sector depends on various factors like, performance of the company, market conditions, company valuation and IPO Size. PE Ratio varies from sector to sector and company to company. Know the average PE Multiple in each sector.
Currently 25 companies are listed under Pharmaceutical sector. Based on the latest data from the Stock Exchanges. Choose the Best Merchant Banker from the Merchant Banker List
Performance of companies depends on various factors like, profits, future plans, Market share, PE Ratio etc. By assessing these factors investor can make better investment decisions.Integris Medtech Peer comparison provides IPO analysis of companies listed in this sector, on the basis of different Key performance indicators (KPI)like, Listing Gain of peers, current market price, PE Ratio and IPO Size.
Upcoming IPO refers to companies which have filed their DRHP with the Stock exchange and are awaiting approval from NSE or BSE 14 companies have filed their DRHP for IPO under Pharmaceutical sector. .New IPO 2025-2026 and Upcoming IPO
PE Multiple is a metrics that is widely used for IPO Valuation. Merchant bankers in coordination with the company decides the PE Multiple.The PE Multiple depends on various factors and it should be analyzed in coordination with other financial metrics. Know the PE ratio of your company with PE Calculator provided by IPOplatform
Integris Medtech operates in Pharmaceutical and Offers Diversified Medical Products And Laboratory Solutions Company. The Issue is listed on BSE,NSE in Oct, 2025. Integris Medtech IPO size was with Issue price of .
Merchant Banker(s) of Integris Medtech IPO: Axis Capital Limited , Citigroup Global Markets India Private Limited , ICICI Securities Limited , IIFL Securities Limited
Integris Medtech IPO subscription was X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Integris Medtech IPO listed at a listing price of against the offer price of .
The current market price of Integris Medtech is .
Why Us?
